{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:28Z","timestamp":1788791368546,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Hospitals Authority\u2019s Ascent Plan","award":["DFL20241101"],"award-info":[{"award-number":["DFL20241101"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Cancer cachexia is a multifactorial metabolic syndrome characterized by progressive skeletal muscle loss, affecting 30\u201360% of patients with advanced renal cell carcinoma (RCC). It significantly impacts treatment tolerance, quality of life, and prognosis, yet its diagnosis and management remain challenging due to fragmented RCC-specific evidence, particularly in the era of immune checkpoint inhibitor (ICI)-based therapy. The pathogenesis involves persistent systemic inflammation, metabolic reprogramming, and tumor\u2013host interactions. The IL-6\/STAT3 and TNF-\u03b1\/NF-\u03baB pathways are central to muscle catabolism, while tumor-derived mediators such as GDF15 and PTHrP, along with mitochondrial dysfunction, further drive cachexia progression. For prognostic assessment, CT-derived skeletal muscle mass evaluation combined with systemic inflammatory and nutritional biomarkers\u2014including neutrophil-to-lymphocyte ratio (NLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), and cachexia index (CXI)\u2014has improved risk stratification in advanced RCC. Preclinical and emerging clinical data suggest that targeted therapies may partially attenuate cachexia by modulating inflammatory signaling, while multimodal interventions integrating nutritional support and exercise rehabilitation remain the cornerstone of management. Novel strategies, such as inhibition of the GDF15\/GFRAL axis, are under active investigation. Future research should prioritize identification of early biomarkers, standardization of cachexia assessment, and prospective evaluation of cachexia-directed interventions in the immunotherapy era. Integrating cachexia assessment into routine practice may ultimately enable personalized treatment and improve long-term outcomes for patients with advanced RCC.<\/jats:p>","DOI":"10.3390\/ijms27177944","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:53:28Z","timestamp":1788789208000},"page":"7944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Cachexia in Advanced Renal Cell Carcinoma: From Molecular Mechanisms to Prognostic Assessment"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2426-7908","authenticated-orcid":false,"given":"Yushuang","family":"Cui","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5544-3339","authenticated-orcid":false,"given":"Yudong","family":"Cao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchao","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Du","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/jcsm.13323","article-title":"Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia","volume":"14","author":"Arai","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1038\/s41598-017-07955-6","article-title":"Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients","volume":"7","author":"Gu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.clgc.2016.08.004","article-title":"Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy","volume":"15","author":"Fukushima","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/cncr.34174","article-title":"Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"128","author":"Khan","year":"2022","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Liu, Q., Yang, J., Chen, X., Yang, J., Zhao, X., Huang, Y., Lin, Y., and Pu, J. (2022). Prognostic significance of sarcopenia and systemic inflammation for patients with renal cell carcinoma following nephrectomy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1047515"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s10147-026-03041-y","article-title":"Cachexia index as a prognostic indicator in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: Multicenter analysis","volume":"31","author":"Yamashita","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"494.e1","DOI":"10.1016\/j.urolonc.2022.07.018","article-title":"Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma","volume":"40","author":"Aslan","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.18632\/oncotarget.2812","article-title":"Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle","volume":"6","author":"Pretto","year":"2015","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/15384101.2015.1010979","article-title":"Inactivating STAT3: Bad for tumor, good for muscle","volume":"14","author":"Piccirillo","year":"2015","journal-title":"Cell Cycle"},{"key":"ref_14","first-page":"317","article-title":"TNF alpha, IL-1 beta and IL-6 production by peripheral blood monocytes in patients with renal cell carcinoma","volume":"20","author":"Ikemoto","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/CM9.0000000000003876","article-title":"Decoding GDF15: Impact on prostate cancer metabolism, chemoresistance, and clinical applications","volume":"139","author":"Zhu","year":"2026","journal-title":"Chin. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Akdogan, O., Turkmen, S., Uyar, G.C., Yucel, K.B., Tufekci, B., Gurler, F., Yazici, O., Ozdemir, N., Ozet, A., and Karakaya, C. (2024). Impact of Serum GDF-15 and IL-6 on Immunotherapy Response in Cancer: A Prospective Study. Cancers, 16.","DOI":"10.3390\/cancers16244146"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.cmet.2021.08.012","article-title":"The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy","volume":"33","author":"Wei","year":"2021","journal-title":"Cell Metab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tomida, R., Ozaki, K., Tanaka, Y., Komatsu, R., Hirata, S., Uchida, T., Furukawa, J., Nikawa, T., and Fukawa, T. (2026). Regulatory mechanisms of mitochondrial function by cancer-derived exosomes in cachexia. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1715589"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ipek, O.M., Dincer, E., Aydiner, O., Sevinc, A.H., Hanci Sevinc, B., and Aras, E. (2026). Preoperative Psoas Muscle Index and Psoas Attenuation in Patients Undergoing Nephrectomy for Renal Cell Carcinoma: A Retrospective Cohort Study. Medicina, 62.","DOI":"10.3390\/medicina62061155"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11934-023-01157-6","article-title":"Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma","volume":"24","author":"Schmeusser","year":"2023","journal-title":"Curr. Urol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/JU.0000000000001196","article-title":"Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors","volume":"204","author":"Takemura","year":"2020","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102434","DOI":"10.1016\/j.clgc.2025.102434","article-title":"The Impact of Computed Tomography-Defined Sarcopenia on Surgical Outcomes in Patients with Sarcomatoid Renal Cell Carcinoma: A Comprehensive Assessment of Abdominal, Psoas, and Paraspinal Musculature","volume":"23","author":"Liu","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12957-025-04079-4","article-title":"The role of preoperative sarcopenia in post-nephrectomy prognosis of renal cell carcinoma: An integrated systematic review and meta-analysis","volume":"23","author":"Guo","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/COC.0000000000000061","article-title":"Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib","volume":"40","author":"Cushen","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"291.e27","DOI":"10.1016\/j.urolonc.2024.04.008","article-title":"Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma","volume":"42","author":"Ishihara","year":"2024","journal-title":"Urol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s00330-022-09345-7","article-title":"Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: A multicenter, retrospective study","volume":"33","author":"Wang","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_27","first-page":"20260012","article-title":"Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia","volume":"11","author":"Okamura","year":"2026","journal-title":"Prog. Rehabil. Med."},{"key":"ref_28","first-page":"283","article-title":"A study on the relationship between the production of cytokines and the biological features of cachexia using renal cell carcinoma heterotransplanted to nude mice","volume":"86","author":"Onishi","year":"1995","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kays, J.K., Koniaris, L.G., Cooper, C.A., Pili, R., Jiang, G., Liu, Y., and Zimmers, T.A. (2020). The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12061605"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/ki.2014.285","article-title":"TNF receptors: Signaling pathways and contribution to renal dysfunction","volume":"87","author":"Mayadas","year":"2015","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhou, H., Wang, C., Ou, C., Lao, Y., Luo, Y., Lao, M., Liu, J., Xie, J., and Huang, H. (2026). Insulin resistance-related indices, sarcopenia, and cardiovascular risk in CKM stages 1-3: A prospective cohort study from CHARLS. BMC Endocr. Disord., 26.","DOI":"10.1186\/s12902-026-02305-y"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.33462","article-title":"Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma","volume":"127","author":"Higgins","year":"2021","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","article-title":"Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment","volume":"11","author":"Ishihara","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Remaily, B.C., Young, G., Lathrop, H., Thomas, J., Kim, K., Vu, T.T., Adeluola, A., Stanton, C., Mulcahy, G., and Xie, Z. (2025). Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1669979"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.trsl.2026.02.009","article-title":"Exploring the role of chemerin in skeletal muscle phenotype in those with kidney disease","volume":"290","author":"Baker","year":"2026","journal-title":"Transl. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11523-020-00744-8","article-title":"Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib","volume":"15","author":"Buchler","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11523-018-0600-3","article-title":"Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma","volume":"13","author":"Ishihara","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2478\/raon-2025-0065","article-title":"Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab","volume":"59","author":"Ozkan","year":"2025","journal-title":"Radiol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hu, Q., Mao, W., Wu, T., Xu, Z., Yu, J., Wang, C., Chen, S., Chen, S., Xu, B., and Xu, Y. (2021). High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated With Sarcopenia Risk in Hospitalized Renal Cell Carcinoma Patients. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.736640"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jcsm.12025","article-title":"Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma","volume":"6","author":"Gu","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e48992","DOI":"10.1097\/MD.0000000000048992","article-title":"A CT-based radiomics model for noninvasive prediction of MMP9 expression and prognostic evaluation in renal cell carcinoma","volume":"105","author":"Sun","year":"2026","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tamir, S., Behar, H.V., Tal, R., Jasper, R.T., Armoni, M., Aloni, H.P., Orad, R.I., Voet, H., Atar, E., and Grubstein, A. (2026). CT Body Composition Changes Predict Survival in Immunotherapy-Treated Cancer Patients: A Retrospective Cohort Study. Cancers, 18.","DOI":"10.3390\/cancers18020341"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/j.clgc.2023.05.006","article-title":"Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab","volume":"21","author":"McManus","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1245\/s10434-018-6652-x","article-title":"Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue Features in Relation to Short-Term Outcomes After Elective Surgery for Colorectal Cancer: A Multicenter Approach","volume":"25","author":"Martin","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00228-021-03199-6","article-title":"Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients","volume":"78","author":"Abe","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Rolley, C., Zidane, M., Nedelcu, C., Barth, M., Saulnier, P., Procaccio, V., and Bigot, P. (2026). Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study. Nutrients, 18.","DOI":"10.21203\/rs.3.rs-8927906\/v1"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13732","DOI":"10.1002\/jcsm.13732","article-title":"Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2","volume":"16","author":"Laird","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMc2500502","article-title":"Ponsegromab for the Treatment of Cancer Cachexia","volume":"392","author":"Nielsen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/14796694.2026.2654735","article-title":"GLP-1 receptor agonists and immune checkpoint inhibitor therapy: A narrative review on mechanistic and clinical evidence","volume":"22","author":"Frey","year":"2026","journal-title":"Future Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13679-026-00707-6","article-title":"The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation","volume":"15","author":"Albor","year":"2026","journal-title":"Curr. Obes. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1042\/BST20260486","article-title":"Pro-inflammatory cytokine-driven molecular signaling in skeletal muscle during cancer cachexia","volume":"54","author":"Pati","year":"2026","journal-title":"Biochem. Soc. Trans."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1200\/JCO.23.01965","article-title":"Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/jcsm.13638","article-title":"Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study","volume":"15","author":"Du","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: An open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: A randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15141","DOI":"10.1038\/s41598-021-94565-y","article-title":"The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia","volume":"11","author":"Cheung","year":"2021","journal-title":"Sci. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:57:03Z","timestamp":1788789423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":58,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177944"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177944","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}